Compounds > iproniazid

iproniazid and phentermine

iproniazid has been researched along with phentermine in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (28.57)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	3 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Seiler, KU; Wasserman, O	1
Opitz, K; Weischer, ML	1
Maher, TJ; Ulus, IH; Wurtman, RJ	1

Reviews

1 review(s) available for iproniazid and phentermine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

6 other study(ies) available for iproniazid and phentermine

Article	Year
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
MAO-inhibitory properties of anorectic drugs. The Journal of pharmacy and pharmacology, 1973, Volume: 25, Issue:7 Topics: Animals; Appetite Depressants; Chlorphentermine; Dose-Response Relationship, Drug; Hypertension, Pulmonary; In Vitro Techniques; Iproniazid; Lung; Methysergide; Mitochondria, Liver; Monoamine Oxidase Inhibitors; Oxazoles; Phenmetrazine; Phentermine; Rats; Serotonin Antagonists	1973
[The excretion of anorectic phenylalkylamines in the urine]. Arzneimittel-Forschung, 1966, Volume: 16, Issue:10 Topics: Animals; Appetite Depressants; Carbamates; Chlorphentermine; Chromatography, Thin Layer; Fenfluramine; Fluorine; Iproniazid; Male; Phenethylamines; Phentermine; Rats	1966
Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochemical pharmacology, 2000, Jun-15, Volume: 59, Issue:12 Topics: Animals; Antidepressive Agents; Brain; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Interactions; Ephedrine; Iproniazid; Liver; Lung; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phentermine; Rats; Rats, Sprague-Dawley	2000